首页> 外文期刊>Journal of Ethnopharmacology: An Interdisciplinary Journal Devoted to Bioscientific Research on Indigenous Drugs >Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification
【24h】

Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification

机译:基于网络药理学和实验验证,对复活注射治疗冠状病毒疾病(Covid-19)的新机制

获取原文
获取原文并翻译 | 示例
           

摘要

Ethnopharmacological relevance: Reduning injection (RDNI) is a patented Traditional Chinese medicine that contains three Chinese herbal medicines, respectively are the dry aboveground part of Artemisia annua L., the flower of Lonicera japonica Thunb., and the fruit Gardenia jasminoides J.Ellis. RDNI has been recommended for treating Coronavirus Disease 2019 (COVID-19) in the ?New Coronavirus Pneumonia Diagnosis and Treatment Plan". Aim of the study: To elucidate and verify the underlying mechanisms of RDNI for the treatment of COVID-19. Methods: This study firstly performed anti-SARS-CoV-2 experiments in Vero E6 cells. Then, network pharmacology combined with molecular docking was adopted to explore the potential mechanisms of RDNI in the treatment for COVID-19. After that, western blot and a cytokine chip were used to validate the predictive results. Results: We concluded that half toxic concentration of drug CC50 (dilution ratio) = 1:1280, CC50 = 2.031 mg crude drugs/mL (0.047 mg solid content/mL) and half effective concentration of drug (EC50) (diluted multiples) = 1:25140.3, EC50 = 103.420 ?g crude drugs/mL (2.405 ?g solid content/mL). We found that RDNI can mainly regulate targets like carbonic anhydrases (CAs), matrix metallopeptidases (MMPs) and pathways like PI3K/AKT, MAPK, Forkhead box O s and T cell receptor signaling pathways to reduce lung damage. We verified that RDNI could effectively inhibit the overexpression of MAPKs, PKC and p65 nuclear factor-?B. The injection could also affect cytokine levels, reduce inflammation and display antipyretic activity. Conclusion: RDNI can regulate ACE2, Mpro and PLP in COVID-19. The underlying mechanisms of RDNI in the treatment for COVID-19 may be related to the modulation of the cytokine levels and inflammation and its antipyretic activity by regulating the expression of MAPKs, PKC and p65 nuclear factor NF-?B.
机译:民族药理学相关性:热毒宁注射液(RDNI)是一种获得专利的中药,含有三种中草药,分别是青蒿的干燥地上部分、金银花的花。,还有栀子。RDNI被推荐用于治疗2019年冠状病毒病(COVID-19)?新的冠状病毒肺炎诊断和治疗计划2019冠状病毒疾病2019冠状病毒疾病的治疗:目的:阐明和验证RDNI治疗COVID-19的机制。方法:首先在韦罗E6细胞中进行抗SARS COV-2实验,然后采用分子药理学和分子药理学对接的方法,研究RDNI在COVID-19治疗中的作用机制,并应用Western blot和细胞因子芯片进行V V基因的检测。验证预测结果。结果:我们得出结论:药物半数毒性浓度CC50(稀释比)=1:1280,CC50=2.031mg生药/mL(固体含量0.047mg/mL),药物半数有效浓度EC50(稀释倍数)=1:25140.3,EC50=103.420?g生药/mL(2.405?g固体含量/mL)。我们发现RDNI主要通过调节碳酸酐酶(CAs)、基质金属肽酶(MMPs)等靶点和PI3K/AKT、MAPK、Forkhead box和T细胞受体信号通路来减轻肺损伤。我们证实RDNI能有效抑制MAPKs、PKC和p65核因子-的过度表达?B.注射也可以影响细胞因子水平,减轻炎症,并显示解热活性。结论:2019冠状病毒疾病可调节COVID-19的ACE2、MPRO和PLP。MAPKs 2019冠状病毒疾病的治疗机制可能与调节细胞因子水平、炎症反应及解热活性有关,通过调节细胞因子的表达,调节PKC、p65和N65的表达。B

著录项

  • 来源
  • 作者单位

    Beijing Univ Chinese Med Sch Chinese Mat Medial Dept Clin Chinese Pharm 11 North Three Ring East;

    Univ Macau Inst Chinese Med Sci State Key Lab Qual Res Chinese Med Macau 999078 Peoples R China;

    Beijing Univ Chinese Med Sch Chinese Mat Medial Dept Clin Chinese Pharm 11 North Three Ring East;

    Beijing Univ Chinese Med Sch Chinese Mat Medial Dept Clin Chinese Pharm 11 North Three Ring East;

    Beijing Univ Chinese Med Sch Chinese Mat Medial Dept Clin Chinese Pharm 11 North Three Ring East;

    Beijing Univ Chinese Med Sch Chinese Mat Medial Dept Clin Chinese Pharm 11 North Three Ring East;

    Beijing Univ Chinese Med Sch Chinese Mat Medial Dept Clin Chinese Pharm 11 North Three Ring East;

    Beijing Univ Chinese Med Sch Chinese Mat Medial Dept Clin Chinese Pharm 11 North Three Ring East;

    Beijing Univ Chinese Med Sch Chinese Mat Medial Dept Clin Chinese Pharm 11 North Three Ring East;

    State Key Lab New Tech Chinese Med Pharmaceut Pro Lianyungang 222001 Jiangsu Peoples R China;

    State Key Lab New Tech Chinese Med Pharmaceut Pro Lianyungang 222001 Jiangsu Peoples R China;

    State Key Lab New Tech Chinese Med Pharmaceut Pro Lianyungang 222001 Jiangsu Peoples R China;

    State Key Lab New Tech Chinese Med Pharmaceut Pro Lianyungang 222001 Jiangsu Peoples R China;

    Beijing Univ Chinese Med Sch Chinese Mat Medial Dept Clin Chinese Pharm 11 North Three Ring East;

    Beijing Univ Chinese Med Sch Chinese Mat Medial Dept Clin Chinese Pharm 11 North Three Ring East;

    Beijing Univ Chinese Med Sch Chinese Mat Medial Dept Clin Chinese Pharm 11 North Three Ring East;

    Beijing Univ Chinese Med Sch Chinese Mat Medial Dept Clin Chinese Pharm 11 North Three Ring East;

    State Key Lab New Tech Chinese Med Pharmaceut Pro Lianyungang 222001 Jiangsu Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;
  • 关键词

    Reduning injection; COVID-19; Network pharmacology; SARS-CoV-2; Molecular docking; Western blot;

    机译:修复注射;Covid-19;网络药理学;SARS-COV-2;分子对接;Western Blot;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号